Extended Spectrum Beta-Lactamases In Escherichia Coli & Klebsiella Spp - Prevalence, Associated Risk Factors And Clinical Outcome In Hospitalized Patients.
Extended Spectrum Beta-Lactamases In Escherichia Coli & Klebsiella Spp
Keywords:
ESBL prevalence, risk factors, clinical outcomeAbstract
Objective: Infection by extended spectrum beta-lactamase (ESBL) producing strains of Escherichia coli and Klebsiella spp. is variably associated with presence of co-morbid conditions, predisposing factors and poor outcome. Objective of this study was to determine the prevalence of ESBL producing strains along with the outcome and risk factors in patients infected with such strains. Materials and Methods: This observational study was conducted on 6910 clinical samples. E coli & Klebsiella spp. were identified with detection of ESBL production according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Patients’ clinical and demographic details along with risk factors and co-morbid conditions, type of response to antimicrobial therapy, length of hospital stay and mortality were collected. Results: 69.62% out of 563 E.coli and 62.80% out of 342 Klebsiella spp. were isolated from 6910 samples were ESBL producers respectively. Male:Female ratio was 1.36:1 and 2.37:1 for E coli and Klebsiella spp. respectively. Blood Stream Infection (p=.006), soft tissue infections (p=0.08), genital tract infections (p=0.03) and admission in intensive care units were significantly associated with risk of infection by Klebsiella spp. Immunosuppressive therapy (p=0.02) and diabetes mellitus (p=0.04) were significant comorbid conditions in ESBL producing E coli infections. The mean duration of hospital stay for ESBL producing E coli and Klebsiella spp. was 13.65 ± 12.6 and 17.89 ± 14.76 days with mortality of 8.6% and 13.34% respectively. Conclusions: Several co-morbid conditions and invasive devices were significantly associated with infection by ESBL-producing, strains of E. coli and Klebsiella spp. with longer duration of hospital stay and increased mortality in comparison to ESBL non-producers.[ Singh S et al NJIRM 2014; 5(2) :75-81]
References
2. Zahar JR, Lortholary O, Martin C, Potel G, Plesiat P, Nordmann P. Addressing the challenge of extended spectrum beta-lactamases. Curr Opin Investig Drugs. 2009;10:172-80.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk tests; Approved Standards, 9th ed. CLSI Document M2- A9;26 (1). Wayne PA: 2006
4. Khanfar HS, Bindayna KM, Senok AC, Botta GA Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae:trends in the hospital and community settings. J Infect Dev Ctries. 2009;3:295-99.
5. Ali AM, Rafi S, Qureshi AH Frequency of extended spectrum beta lactamase producing gram negative bacilli among clinical isolates at clinical laboratories of Army Medical College, Rawalpindi. J Ayub Med Coll Abbottabad. 2004;16:35-37.
6. Babypadmini S, Appalaraju B. Extended-spectrum β -lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22:172-74
7. Tankhiwale SS., Jalgaonkar SV., Ahamad S & Hassani U Evaluation of extended spectrum beta lactamase in urinary isolates Indian J Med Res 2004;120: 553-56
8. Menon T, Bindu D, Kumar CP, Nalini S, Thirunarayan MA. Comparison of double disc and three dimensional methods to screen for ESBL producers in a tertiary care hospital Indian J Med Microbiol. 2006;24:117-20.
9. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R et al Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome J Antimicrob Chemother 2010; 65:333-41.
10. Mahesh E, Ramesh D, Indumathi V.A, Punith K, Kirthi R and Anupama H.A, Complicated Urinary Tract Infection in a Tertiary Care Center in South India. Al Ameen J Med Sci 2010;3 :1 2 0 - 2 7
11. Shivaprakasha S., Radhakrishnan K., Gireesh A. & Shamsul K P. Routine Screening for ESBL Production, a Necessity of Today. The Internet Journal of Microbiology. 2007; 3
12. Piroth L, Aube H, Doise JM, Martin MV. Spread of ESBL - producing K. pneumoniae. Are -lactamase inhibitors of therapeutic value? Clin Infect Dis 1998;27:76-80
13. Rao Sridhar PN, Basavarajappa KG, Krishna GL. Detection of extended spectrum beta-lactamase from clinical isolates in Davangere. Indian J Pathol Microbiol 2008;51:497-9
14. Superti SV, Augusti G, Zavascki AP Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream
infections. Rev Inst Med Trop Sao Paulo. 2009 ;51:211-16
15. Goyal A, Prasad KN, Prasad A, Gupta S, Ghoshal U, Ayyagari A. Extended spectrum beta-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors. Indian J Med Res 2009;129:695-700
16. Lee CI, Lee NY, Yan JJ, Lee HC, Ko NY, Chang CM et al Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia. J Microbiol Immunol Infect 2009; 42:303-9.
17. Khanfar HS, Bindayna KM, Senok AC, Botta GA Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J Infect Dev Ctries. 2009;3:295-99.
18. Tumbarello M, Sali M, Trecarichi E M, Leone F, Rossi M, Fiori B, et al Bloodstream Infections Caused by Extended-Spectrum β Lactamase-Producing Escherichia coli: Risk Factors for Inadequate Initial Antimicrobial Therapy Antimicrob Agents Chemother. 2008;52:3244–52.
19. Ozgunes I, Erben N, Kiremitci A, Kartal ED, Durmaz G, Colak H et al. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors. Saudi Med J 2006; 27:608-12.
20. Shiju M P, Yashavanth R, Narendra N. Detection of extended spectrum beta-lactamase production and multidrug resistance in clinical isolates of E.coli and K.pneumoniae in Mangalore. Journal of Clinical and Diagnostic Research. 2010; 4:2442-45
21. Shakil S, Ali SZ, Akram M, Ali SM, Khan AU. Risk factors for extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae acquisition in a neonatal intensive care unit. J Trop Pediatr. 2010; 56:90-6.
22. Kang CI, Kin SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Bloodstream Infections Due to Extended-Spectrum_-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on AntimicrobialTherapy. Antimicrob Agents Chemother. 2004;48: 4574–81.
23. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257-62.
